Literature DB >> 20626467

Blockage of Notch1 signaling modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients.

Jinxian Pei1, Zhenghao Tang, Guoqing Zang, Yongsheng Yu.   

Abstract

AIM: Chronic hepatitis B virus (HBV) infection is thought to involve the imbalance of T-helper (Th)1/Th2 cells. Many procedures found Notch signaling involved the proliferation and differentiation of T lymphocytes during development and peripheral functions. The aim of this study was to discover the effect of blockage of Notch1 signaling to Th cells and the mechanisms involved in chronic hepatitis B patients.
METHODS: CD4(+) T cells from hepatitis B patients and healthy volunteers were isolated, and Notch1 expression of CD4(+) T cells was determined by reverse transcription polymerase chain reaction (RT-PCR). Blockage of Notch1 signaling of peripheral blood mononuclear cells (PBMC) from chronic hepatitis B patients, Th1- and Th2-type cytokines were assayed by enzyme-linked immunosorbent assay and levels of T-bet, GATA-3 mRNA were measured by RT-PCR.
RESULTS: Notch1 expression of CD4(+) T cells from chronic hepatitis B patients was upregulated, on the contrary to that from acute hepatitis B patients and healthy volunteers. Blockage of Notch1 signaling can strongly inhibit the production of Th2-type cytokines and the expression of GATA-3; the production of Th1-type cytokines and the expression of T-bet, however, were enhanced.
CONCLUSION: Blockage of Notch1 signaling could regulate the immune balance of Th1/Th2 in chronic hepatitis B patients, which may be mediated partly by regulating transcription factors T-bet and GATA-3.

Entities:  

Year:  2010        PMID: 20626467     DOI: 10.1111/j.1872-034X.2010.00680.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

Review 1.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

2.  Oncogenic role of the Notch pathway in primary liver cancer.

Authors:  Jie Lu; Yujing Xia; Kan Chen; Yuanyuan Zheng; Jianrong Wang; Wenxia Lu; Qin Yin; Fan Wang; Yingqun Zhou; Chuanyong Guo
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

3.  Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma.

Authors:  Wen-Rui Wu; Xiang-De Shi; Rui Zhang; Man-Sheng Zhu; Lei-Bo Xu; Xian-Huan Yu; Hong Zeng; Jie Wang; Chao Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

4.  Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.

Authors:  Bisrat G Debeb; Evan N Cohen; Kimberly Boley; Erik M Freiter; Li Li; Fredika M Robertson; James M Reuben; Massimo Cristofanilli; Thomas A Buchholz; Wendy A Woodward
Journal:  Breast Cancer Res Treat       Date:  2012-05-01       Impact factor: 4.872

5.  Osteopontin promotes dendritic cell maturation and function in response to HBV antigens.

Authors:  Guangying Cui; Jianing Chen; Jianqin He; Chong Lu; Yingfeng Wei; Lin Wang; Xuejun Xu; Lanjuan Li; Toshimitsu Uede; Hongyan Diao
Journal:  Drug Des Devel Ther       Date:  2015-06-12       Impact factor: 4.162

6.  Notch Signaling Contributes to Liver Inflammation by Regulation of Interleukin-22-Producing Cells in Hepatitis B Virus Infection.

Authors:  Xin Wei; Jiu-Ping Wang; Chun-Qiu Hao; Xiao-Fei Yang; Lin-Xu Wang; Chang-Xing Huang; Xue-Fan Bai; Jian-Qi Lian; Ye Zhang
Journal:  Front Cell Infect Microbiol       Date:  2016-10-17       Impact factor: 5.293

7.  Notch signaling facilitates hepatitis B virus covalently closed circular DNA transcription via cAMP response element-binding protein with E3 ubiquitin ligase-modulation.

Authors:  Zijing Wang; Kazunori Kawaguchi; Masao Honda; Shinichi Hashimoto; Takayoshi Shirasaki; Hikari Okada; Noriaki Orita; Tetsuro Shimakami; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Seishi Murakami; Shuichi Kaneko
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.